| 1. |
- Pant, N., et al.
(författare)
-
Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies
- 2007
-
Ingår i: BMC Microbiology. - : Springer Science and Business Media LLC. - 1471-2180. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- Background. Rotavirus is a worldwide cause of infectious infantile diarrhea that claims over 600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy in developing countries, still remains to be proven. Oral delivery of specific immunoglobulins provides passive immunity and is a fast acting treatment for rotavirus diarrhea. Probiotic bacteria have also gained considerable attention lately as treatment for rotavirus diarrhea. Here we report an evaluation of the therapeutic potential of different probiotics and their combination with anti - rotavirus antibodies in a mouse model of rotavirus diarrhea. Results. Of the six probiotic bacteria tested, Lactobacillus rhamnosus strain GG had the strongest influence in reducing prevalence, duration and severity of diarrhea and was therefore chosen for combination treatment with immunoglobulins. The combination treatment reduced the diarrhea outcome measures significantly, prevented histopathological changes and reduced the virus load in the intestines. Conclusion. The advantages associated with immunoglobulins and probiotics based therapy is that the treatment provides a rapid therapeutic effect and is cost efficient. These components do not require special storage conditions and could potentially complement the rehydration therapy that is currently used. © 2007 Pant et al, licensee BioMed Central Ltd.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Marcotte, H, et al.
(författare)
-
Engineered lactobody-producing lactobacilli: a novel form of therapy against rotavirus infection
- 2008
-
Ingår i: FUTURE VIROLOGY. - : Future Medicine Ltd. - 1746-0794 .- 1746-0808. ; 3:4, s. 327-341
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Rotavirus infections remain a major cause of morbidity and mortality worldwide, accounting for an estimated 600,000 deaths each year. New vaccines have been released recently but the lag time between vaccine administration and induction of an immune response can be critical in epidemic situations. A model system has been developed in which Lactobacillus, a ‘Generally Regarded As Safe’ microorganism, can be transformed with antibody fragment-encoding vectors. This allows in situ production of functional variable domains of llama heavy chain antibodies (VHH antibody fragments) against rotavirus in the intestinal tract. The modified bacteria were shown to be protective in a mouse pup model. Our approach represents a novel system for the induction of passive immunity that can be rapidly applied to populations at risk, for example through drinking water, rehydrating solutions or as a food supplement.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Pant, Neha, et al.
(författare)
-
Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea
- 2006
-
Ingår i: Journal of Infectious Diseases. - 0022-1899 .- 1537-6613. ; 194:11, s. 1580-1588
-
Tidskriftsartikel (refereegranskat)abstract
- Background. Rotavirus-induced diarrhea poses a worldwide medical problem in causing substantial morbidity and mortality among children in developing countries. We therefore developed a system for passive immunotherapy in which recombinant lactobacilli constitutively express neutralizing variable domain of llama heavy-chain (VHH) antibody fragments against rotavirus. Methods. VHH were expressed in Lactobacillus paracasei, in both secreted and cell surface-anchored forms. Electron microscopy was used to investigate the binding efficacy of VHH-expressing lactobacilli. To investigate the in vivo function of VHH-expressing lactobacilli, a mouse pup model of rotavirus infection was used. Results. Efficient binding of the VHH antibody fragments to rotavirus was shown by enzyme-linked immunosorbent assay and scanning electron microscopy. VHH fragments expressed by lactobacilli conferred a significant reduction in infection in cell cultures. When administered orally, lactobacilli-producing surface-expressed VHH markedly shortened disease duration, severity, and viral load in a mouse model of rotavirus-induced diarrhea when administered both fresh and in a freeze-dried form. Conclusions. Transformed lactobacilli may form the basis of a novel form of prophylactic treatment against rotavirus infections and other diarrheal diseases. © 2006 by the Infectious Diseases Society of America. All rights reserved.
|
|
